Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe

Core Viewpoint - Samsung Bioepis has commenced the direct commercialization of BYOOVIZ®, a biosimilar to Lucentis (ranibizumab), in Europe [1] Company Summary - Samsung Bioepis is actively entering the European market with its biosimilar product BYOOVIZ® [1]